ClinicalTrials.gg
RecruitingNCT07215910Updated Nov 3, 2026

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

A Phase 3 interventional study of Intensity-Modulated Radiation Therapy and Volume Modulated Arc Therapy in Astrocytoma, IDH-Mutant, Grade 3, sponsored by Alliance for Clinical Trials in Oncology. Recruiting at 177 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Alliance for Clinical Trials in Oncology · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 3, 2026Site recruiting status changed56 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 554 studies in Astrocytoma with a site in United States — 53 open to participants now, 82 under way, 7 of them phase 3. Astrocytoma · United States.

Planned enrollment
5th of 458
408 · median 30
Started
2026
with 14 others
Phase 3
26 of 554
3 open now
Primary completion
2033-05
later than 78 of 81 live
Registered
539th of 554
by date
Lead sponsor
9 of 554
Alliance for Clinical Trials in Oncology

Among the 554 studies in Astrocytoma with a site in United States, this one is the 5th largest by planned enrollment of the 458 interventional ones that give a count, is one of 15 that started in 2026, is one of 26 in phase 3, reaches primary completion later than 78 of the 81 other live ones, and was the 539th registered.

Astrocytoma

690 studies on the registry are indexed under Astrocytoma; 82 are open to participants now.

Browse Astrocytoma studies →

Open to participants now

53 of the 554 studies in Astrocytoma with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Astrocytoma studies recruiting now, 40 (59%) set no upper age limit and 14 (21%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 554 studies in Astrocytoma with a site in United States, or all of them as a file.
02

Study summary

This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Vorasidenib citrate blocks the proteins made by the mutated IDH1 and IDH2 genes, which may help keep tumor cells from growing. It is a type of enzyme inhibitor and a type of targeted therapy. Adding vorasidenib to the usual treatment, temozolomide, may be more effective than temozolomide alone in treating patients with newly diagnosed grade 3 astrocytoma after radiation therapy.

Read the detailed description

The primary and secondary objectives of the study:

PRIMARY OBJECTIVE:

I. To determine if vorasidenib citrate (vorasidenib) and adjuvant temozolomide following radiation therapy improves progression-free survival (PFS) per blinded independent review in patients with newly-diagnosed IDH-mutant astrocytoma (World Health Organization [WHO] grade 3) compared to placebo given with adjuvant temozolomide following radiation therapy.

SECONDARY OBJECTIVES:

I. To evaluate the safety and tolerability of vorasidenib versus (vs.) placebo in combination with temozolomide, following radiation therapy.

II. To evaluate PFS associated with vorasidenib vs. placebo in combination with temozolomide following radiation therapy, defined by local institutional review.

III. To evaluate the efficacy of vorasidenib vs. placebo in combination with adjuvant temozolomide, following radiation therapy, based on overall survival (OS).

IV. To evaluate the efficacy of vorasidenib vs. placebo in combination with temozolomide, following radiation therapy, based on objective response rate (ORR), complete response (CR) + partial response (PR), time to response, time to CR+PR, duration of response, and duration of CR+PR, with response assessed per the blinded independent review using the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria in patients with measurable tumor at baseline.

V. To evaluate the efficacy of vorasidenib vs. placebo in combination with temozolomide, following radiation therapy, based on ORR, CR+PR, time to response, time to CR+PR, duration of response, and duration of CR+PR, with response assessed per local institutional review or investigator using the RANO 2.0 criteria.

VI. To evaluate the efficacy of vorasidenib vs. placebo in combination with temozolomide, following radiation therapy, based on time to next intervention.

VII. To evaluate vorasidenib vs. placebo in combination with temozolomide, following radiation, with respect to health-related quality of life (HRQoL) as assessed by the Functional Assessment of Cancer Therapy-Brain (FACT-Br) and symptom burden as assessed by the MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT).

EXPLORATORY OBJECTIVES:

I. To correlate tumor genotype with PFS. II. To evaluate the effect of the addition of vorasidenib to adjuvant temozolomide on seizure control.

OUTLINE: Patients are randomized 1:1 to 1 of 2 arms.

ARM I (CONTROL): Patients receive intensity-modulated radiation therapy (IMRT)/volume modulated arc therapy (VMAT) or pencil beam scanning (PBS) or intensity-modulated proton therapy (IMPT) once daily (QD) on Monday-Friday for 33 fractions. Starting 4 weeks after radiotherapy, patients receive temozolomide orally (PO) QD on days 1-5 and placebo PO QD on days 1-28 of each cycle. Cycles of combination treatment repeat every 28 days for up to 12 months and placebo alone repeats every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and magnetic resonance imaging (MRI) throughout the study.

ARM II (EXPERIMENTAL): Patients receive IMRT/VMAT or PBS or IMPT QD on Monday-Friday for 33 fractions. Starting 4 weeks after radiotherapy, patients receive temozolomide PO QD on days 1-5 and vorasidenib PO QD on days 1-28 of each cycle. Cycles of combination treatment repeat every 28 days for up to 12 months and vorasidenib alone repeats every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI throughout the study.

After completion of study treatment, patients are followed up every 3 months for the first 2 years, every 4 months for the next 2 years, and then every 6 months for up to 10 years.

03

Conditions studied

  • Astrocytoma, IDH-Mutant, Grade 3
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • STEP 0: Histologic diagnosis of astrocytoma, IDH-mutant (central nervous system [CNS] WHO grade 3)
  • STEP 0: Available diagnostic slides (hematoxylin and eosin staining method [H\&E] and immunohistochemical stains for central review)
  • STEP 0: Tissue available for central biomarker testing (CDKN2A/B and1p/19q co-deletion [all patients], and IDH1/IDH2 [if needed])
  • STEP 1: Centrally-confirmed diagnosis of astrocytoma, IDH-mutant (CNS WHO grade 3)
  • STEP 1: Presence of IDH1 p.R132 or IDH2 p.172 mutation, confirmed by central review of immunohistochemical stain or molecular testing results, with central confirmation of equivocal results
  • STEP 1: Absence of CDKN2A/B homozygous deletion by central testing
  • STEP 1: Absence of whole arm 1p/19q co-deletion (i.e. intact 1p/19q) by central testing
  • STEP 1: No evidence of spinal or
  • STEP 1: No prior chemotherapy, cranial irradiation, IDH-inhibitor therapy, radiotherapy, vaccine therapy, small-molecule therapy, or laser ablation
  • STEP 1: Prior diagnostic surgery/resection/ ≤ 6 months of registration
  • STEP 1: Planned radiotherapy and chemotherapy
  • STEP 1: Age ≥ 12 years
  • STEP 1: (ECOG) performance status ≤ 2 (or performance status [KPS] ≥ 60%)
  • STEP 1: (ANC) ≥ 1,500/mm\^3
  • STEP 1: ≥ 9 g/dL
  • STEP 1: count ≥ 100,000/mm\^3
  • STEP 1: Total ≤ 1.5 x (ULN)

    * For patients with Gilbert syndrome, total bilirubin ≤ 1.0 x ULN

  • STEP 1: (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 x ULN
  • STEP 1: Alkaline phosphatase ≤ 2.5 x ULN
  • STEP 1: Creatinine ≤ 2.0 x ULN or calculated (calc.) > 40 mL/min

    * For patients ≥ 18 years of age, calculated using the Cockcroft-Gault equation. For patients \< 18 years of age, calculated using the Bedside Schwartz method:

    • Age: 10 to \< 13 years; Maximum Serum Creatinine (mg/dL): 1.2 (male) 1.2 (female)
    • Age: 13 to \< 16 years; Maximum Serum Creatinine (mg/dL): 1.5 (male) 1.4 (female)
    • Age: ≥ 16 years; Maximum Serum Creatinine (mg/dL): 1.7(male) 1.4 (female)
  • STEP 1: Not pregnant and not nursing, because this study involves agents whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are unknown

    * Therefore, for women of only, a negative pregnancy test done ≤ 14 days prior to registration is required

  • STEP 1: Women and men of should agree to abstain from sexual intercourse or use two highly effective methods of , at least one of which must be a barrier method, throughout their participation in this study and for at least 90 days after the last dose of vorasidenib. Reproductive status and discussions about birth control measures should be documented in the patient's record. Abstinence is acceptable only as true abstinence when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of birth control. Highly effective forms of birth control are defined as hormonal oral contraceptives, injectables, patches, intrauterine devices, intrauterine hormone release systems, bilateral tubal ligation, condoms with spermicide, or male partner sterilization
  • STEP 1: No severe or intercurrent illness, no active infection that requires systemic anti-infective therapy, and no active infection with an unexplained fever > 38.5°C within 7 days prior to registration
  • STEP 1: Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial
  • STEP 1: Patients must be able to tolerate or undergo an MRI
  • STEP 1: Patients with known infection on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial
  • STEP 1: For patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • STEP 1: Patients with a history of virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • STEP 1: No significant active cardiac disease within 6 months prior to registration, including Functional Classification class III or IV congestive heart failure, myocardial infarction, unstable angina, and/or stroke. To be eligible for this trial, patients should be class 2B or better
  • STEP 1: No history of significant (grade ≥ 2) intratumoral or peri-tumoral hemorrhage
  • STEP 1: No known active inflammatory gastrointestinal disease, chronic diarrhea, prior gastric resection or lap band dysphagia, short-gut syndrome, gastroparesis, or other condition causing an inability to swallow oral formulations of agents. Gastroesophageal reflux disease under medical treatment is allowed (assuming no drug interaction potential)
  • STEP 1: No known to any of the components of vorasidenib or temozolomide
  • STEP 1: No other acute or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation or protocol therapy administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study
  • STEP 1: No concurrent use of other investigational agents
  • STEP 1: No concurrent use of alternating tumor treating field (TTField) therapy
  • STEP 1: No concurrent use of therapeutic doses of for glioma. Concurrent use of physiologic doses of steroids (defined as equivalent of ≤ 10 mg prednisone daily) for medical conditions unrelated to glioma is allowed. Corticosteroids administered for reasons related to glioma should be used in the smallest dose possible to control symptoms of cerebral edema and mass effect and discontinued whenever possible.
  • STEP 1: No concurrent use of warfarin sodium or any other Coumadin-derivative anticoagulant. Patients must be off Coumadin-derivative anticoagulants for at least 7 days prior to registration. Low molecular weight heparin (LMWH) and factor Xa inhibitors are allowed
  • STEP 1: No concurrent use of strong and moderate CYP1A2 inhibitors, moderate CYP1A2 inducers, or substrates where a minimal concentration change can reduce efficacy. Patients should be transferred to other medications prior to registration

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
408 participants (estimated)

Study arms

  • Placebo comparator
    Arm I (temozolomide, placebo)

    Patients receive IMRT/VMAT or PBS or IMPT QD on Monday-Friday for 33 fractions. Starting 4 weeks after radiotherapy, patients receive temozolomide PO QD on days 1-5 and placebo PO QD on days 1-28 of each cycle. Cycles of combination treatment repeat every 28 days for up to 12 months and placebo alone repeats every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI throughout the study.

    Radiation: Intensity-Modulated Radiation Therapy · Radiation: Volume Modulated Arc Therapy · Radiation: Pencil Beam Scanning · Procedure: Intensity-Modulated Proton Therapy · Drug: Temozolomide · Drug: Placebo Administration · Procedure: Biospecimen Collection · Procedure: Magnetic Resonance Imaging · Other: Questionnaire Administration

  • Experimental
    Arm II (temozolomide, vorasidenib)

    Patients receive IMRT/VMAT or PBS or IMPT QD on Monday-Friday for 33 fractions. Starting 4 weeks after radiotherapy, patients receive temozolomide PO QD on days 1-5 and vorasidenib PO QD on days 1-28 of each cycle. Cycles of combination treatment repeat every 28 days for up to 12 months and vorasidenib alone repeats every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI throughout the study.

    Radiation: Intensity-Modulated Radiation Therapy · Radiation: Volume Modulated Arc Therapy · Radiation: Pencil Beam Scanning · Procedure: Intensity-Modulated Proton Therapy · Drug: Temozolomide · Drug: Vorasidenib · Procedure: Biospecimen Collection · Procedure: Magnetic Resonance Imaging · Other: Questionnaire Administration

Interventions

  • RadiationIntensity-Modulated Radiation Therapy

    Undergo IMRT/VMAT

    Also known as: IMRT

  • RadiationVolume Modulated Arc Therapy

    Undergo IMRT/VMAT

    Also known as: VMAT

  • RadiationPencil Beam Scanning

    Undergo PBS

    Also known as: PBS

  • ProcedureIntensity-Modulated Proton Therapy

    Undergo IMPT

    Also known as: IMPT

  • Given PO

  • Given PO

  • DrugPlacebo Administration

    Given PO

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: MRI

  • OtherQuestionnaire Administration

    Ancillary Studies

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) by blinded independent central review (BICR)

    This is defined as the time from randomization to the time of documented disease progression, as determined by BICR using the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria or death due to any cause. PFS distributions will be evaluated for each arm and will be graphically and quantitatively compared using Kaplan-Meier methods. These methods will be used to estimate the median PFS as well as 2-, 3-, and 5-year estimates for PFS by treatment arm along with corresponding 95% confidence intervals. Cox proportional hazards models will also be used to assess influential factors on PFS both in the univariate and the multivariable settings.

    Time frame: assessed up to 10 years

Secondary outcomes

  1. Progression free survival (PFS) by local review

    This is defined as the time from randomization to the time of documented disease progression, as determined by local (institutional/investigator) review using the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria or death due to any cause. PFS distributions will be evaluated for each arm and will be graphically and quantitatively compared using Kaplan-Meier methods. These methods will be used to estimate the median PFS as well as 2-, 3-, and 5-year estimates for PFS by treatment arm along with corresponding 95% confidence intervals. Cox proportional hazards models will also be used to assess influential factors on PFS both in the univariate and the multivariable settings.

    Time frame: up to 10 years

  2. Incidence of adverse events (AEs)

    AEs will be evaluated by treatment regimen. Will be summarized per the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 and where toxicities will be defined as AEs that are deemed to be at least possibly treatment-related. The maximum grade for each type of treatment-related AE will be recorded for each patient, and the frequency of each will be summarized by treatment arm. Frequency tables and graphical evaluations of AEs and treatment-related AEs will be summarized and evaluated to assess if there are any patterns or differences in the rates or types of AEs.

    Time frame: Up to 30 days after last dose of study treatment

  3. Overall survival (OS)

    This is defined as the time from randomization to the date of death due to any cause. Distributions will be evaluated for each arm using the Kaplan Meier method to calculate 2-, 3-, and 5-year rates along with corresponding 95% confidence intervals. Distributions will be compared between arms using the log rank test.

    Time frame: up to 10 years

  4. Objective response rate (ORR) by blinded independent central review (BICR)

    Will be summarized by treatment arm. This is defined as the proportion of patients with measurable tumor at baseline who achieve a minor, partial, or complete response to therapy divided by the total number of patients with measurable tumor at baseline who were randomized and treated on that arm. Response will be determined by BICR using the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria. Assuming the number of patients who respond to therapy on each arm is binomially distributed, these proportions along with corresponding 95% confidence intervals will be estimated.

    Time frame: up to 10 years

  5. Complete response (CR) + partial response (PR) rate by blinded independent central review (BICR)

    Will be summarized by treatment arm. This is defined as the proportion of patients with measurable tumor at baseline who achieve a partial or complete response to therapy divided by the total number of patients with measurable tumor at baseline who were randomized and treated on that arm. Response will be determined by BICR using the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria. Assuming the number of patients who respond to therapy on each arm is binomially distributed, these proportions along with corresponding 95% confidence intervals will be estimated.

    Time frame: up to 10 years

  6. Time to response by blinded independent central review (BICR)

    Will be summarized by treatment arm. This is defined only for patients with measurable disease at baseline as the time from randomization to the date of response to treatment (minor, partial, or complete), as determined by BICR using the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria. Distributions will be evaluated for each arm using the Kaplan Meier method to calculate 6- and 12-month rates along with corresponding 95% confidence intervals.

    Time frame: up to 10 years

  7. Time to complete response (CR) + partial response (PR) by blinded independent central review (BICR)

    Will be summarized by treatment arm. This is defined only for patients with measurable disease at baseline as the time from randomization to the date of response to treatment (partial or complete), as determined by BICR using the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria. Distributions will be evaluated for each arm using the Kaplan Meier method to calculate 6- and 12-month rates along with corresponding 95% confidence intervals.

    Time frame: up to 10 years

  8. Duration of response by blinded independent central review (BICR)

    Will be summarized by treatment arm for only patients who had measurable disease at baseline and achieved a response (minor, partial, or complete) while on treatment, as determined by BICR using the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria. This is defined as the time from the date of response to treatment (minor, partial, or complete) until the date of progression, as determined by BICR. Distributions will be evaluated for each arm using the Kaplan Meier method to calculate 1- and 2-year rates along with corresponding 95% confidence intervals.

    Time frame: up to 10 years

  9. Duration of Complete response (CR) + partial response (PR) by blinded independent central review (BICR)

    Will be summarized by treatment arm for only patients who had measurable disease at baseline and achieved a response (partial or complete) while on treatment, as determined by BICR using the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria. This is defined as the time from the date of response to treatment (partial or complete) until the date of progression, as determined by BICR. Distributions will be evaluated for each arm using the Kaplan Meier method to calculate 1- and 2-year rates along with corresponding 95% confidence intervals.

    Time frame: up to 10 years

  10. Objective response rate (ORR) by local review

    Will be summarized by treatment arm. This is defined as the proportion of patients with measurable tumor at baseline who achieve a minor, partial, or complete response to therapy divided by the total number of patients with measurable tumor at baseline who were randomized and treated on that arm. Response will be determined by local, institutional / investigator review using the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria. Assuming the number of patients who respond to therapy on each arm is binomially distributed, these proportions along with corresponding 95% confidence intervals will be estimated.

    Time frame: up to 10 years

  11. Complete response (CR) + partial response (PR) rate by local review

    Will be summarized by treatment arm. This is defined as the proportion of patients with measurable tumor at baseline who achieve a partial or complete response to therapy divided by the total number of patients with measurable tumor at baseline who were randomized and treated on that arm. Response will be determined by local, institutional / investigator review using the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria. Assuming the number of patients who respond to therapy on each arm is binomially distributed, these proportions along with corresponding 95% confidence intervals will be estimated.

    Time frame: up to 10 years

  12. Time to response by local review

    Will be summarized by treatment arm. This is defined only for patients with measurable disease at baseline as the time from randomization to the date of response to treatment (minor, partial, or complete), as determined by local, institutional / investigator review using the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria. Distributions will be evaluated for each arm using the Kaplan Meier method to calculate 6- and 12-month rates along with corresponding 95% confidence intervals.

    Time frame: up to 10 years

  13. Time to complete response (CR) + partial response (PR) by local review

    Will be summarized by treatment arm. This is defined only for patients with measurable disease at baseline as the time from randomization to the date of response to treatment (partial or complete), as determined by local, institutional / investigator review using the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria. Distributions will be evaluated for each arm using the Kaplan Meier method to calculate 6- and 12-month rates along with corresponding 95% confidence intervals.

    Time frame: up to 10 years

  14. Duration of response by local review

    Will be summarized by treatment arm for only patients who had measurable disease at baseline and achieved a response (minor, partial, or complete) while on treatment, as determined by local, institutional / investigator review using the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria. This is defined as the time from the date of response to treatment (minor, partial, or complete) until the date of progression, as determined by local review. Distributions will be evaluated for each arm using the Kaplan Meier method to calculate 1- and 2-year rates along with corresponding 95% confidence intervals.

    Time frame: up to 10 years

  15. Duration of Complete response (CR) + partial response (PR) by local review

    Will be summarized by treatment arm for only patients who had measurable disease at baseline and achieved a response (partial or complete) while on treatment, as determined by local, institutional / investigator review using the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria. This is defined as the time from the date of response to treatment (partial or complete) until the date of progression, as determined by local review. Distributions will be evaluated for each arm using the Kaplan Meier method to calculate 1- and 2-year rates along with corresponding 95% confidence intervals.

    Time frame: up to 10 years

  16. Time to next therapeutic intervention

    Will be summarized by treatment arm. This is defined as the time from randomization to the time of first subsequent non-protocol treatment. Distributions will be evaluated for each arm using the Kaplan Meier method to calculate 2-, 3-, and 5-year rates along with corresponding 95% confidence intervals.

    Time frame: up to 10 years

Other outcomes

  1. Health related quality of life

    Will be assessed using the Functional Assessment of Cancer Therapy-Brain (FACT-BR). The total score ranges from 0 to 200, with higher score indicating better quality of life.

    Time frame: up to 3 years

  2. Symptom burden

    Will be assessed using the MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT). It consists of 23 symptoms rated on an 11-point scale (0 to 10) to indicate the presence and severity of the symptom, with 0 being "not present" and 10 being "as bad as you can imagine.

    Time frame: up to 3 years

  3. Correlation of tumor genotype with PFS

    Testing of banked biospecimens to determine tumor genotypes will not be conducted until a protocol amendment or separate correlative science proposal is approved. Details of planned statistical analyses will be included in the amendment or proposal.

    Time frame: up to 10 years

  4. Effect of the addition of vorasidenib to adjuvant temozolomide on seizure control

    Results from the MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) question for severity of seizures will be compared between arms.

    Time frame: up to 10 years

07

Study locations

176 of 177 sites recruiting

Showing the first 100 of 177 sites. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for May 2033, 83 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2025
First posted
Oct 14, 2025
StartActual
Jun 24, 2026
Primary completionEst.
May 31, 2033
CompletionEst.
Jan 2040
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
56 sites added. 4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • ProHealth D N Greenwald Center · Mukwonago, United StatesSuspended→Recruiting
  • ProHealth Oconomowoc Memorial Hospital · Oconomowoc, United StatesSuspended→Recruiting
  • UW Cancer Center at ProHealth Care · Waukesha, United StatesSuspended→Recruiting
  • Siteman Cancer Center at West County Hospital · Creve Coeur, United StatesSuspended→Recruiting
Show 56 added (56 United States)
  • Kaiser Permanente Dublin · Dublin, United States
  • Kaiser Permanente-Fremont · Fremont, United States
  • Kaiser Permanente Fresno Orchard Plaza · Fresno, United States
  • Kaiser Permanente-Fresno · Fresno, United States
  • Kaiser Permanente- Modesto MOB II · Modesto, United States
  • Kaiser Permanente-Oakland · Oakland, United States
  • Kaiser Permanente-Roseville · Roseville, United States
  • Kaiser Permanente Downtown Commons · Sacramento, United States
  • Kaiser Permanente-South Sacramento · Sacramento, United States
  • Kaiser Permanente-San Francisco · San Francisco, United States
  • Kaiser Permanente-Santa Teresa-San Jose · San Jose, United States
  • Kaiser Permanente San Leandro · San Leandro, United States
  • Kaiser San Rafael-Gallinas · San Rafael, United States
  • Kaiser Permanente Medical Center - Santa Clara · Santa Clara, United States
  • Kaiser Permanente-Santa Rosa · Santa Rosa, United States
  • Kaiser Permanente-South San Francisco · South San Francisco, United States
  • Kaiser Permanente-Vallejo · Vallejo, United States
  • Kaiser Permanente-Walnut Creek · Walnut Creek, United States
  • John Muir Medical Center-Walnut Creek · Walnut Creek, United States
  • Augusta University Medical Center · Augusta, United States
  • Lawrence Memorial Hospital · Lawrence, United States
  • Massachusetts General Hospital Cancer Center · Boston, United States
  • Dana-Farber Cancer Institute · Boston, United States
  • Abbott-Northwestern Hospital · Minneapolis, United States
  • University of Mississippi Medical Center · Jackson, United States
  • Siteman Cancer Center at Saint Peters Hospital · City of Saint Peters, United States
  • Siteman Cancer Center at West County Hospital · Creve Coeur, United States
  • Washington University School of Medicine · St Louis, United States
  • Siteman Cancer Center-South County · St Louis, United States
  • Siteman Cancer Center at Christian Hospital · St Louis, United States
  • …and 26 more on the registry record
across 2 updates, Oct 2, 2026 – Nov 3, 2026
Site contacts
Changed at 12 sites. See the sites
Show 12 sites
  • Providence Portland Medical Center · Portland, United StatesContact person changed (no phone or email listed)
  • Providence Saint Vincent Medical Center · Portland, United StatesContact person changed (no phone or email listed)
  • University of Vermont Medical Center · Burlington, United StatesContact person changed (no phone or email listed)
  • University of Vermont and State Agricultural College · Burlington, United StatesContact person changed (no phone or email listed)
  • Swedish Medical Center-First Hill · Seattle, United StatesContact added P•••@swedish.org · •••2343Contact added (no phone or email listed)
  • ProHealth D N Greenwald Center · Mukwonago, United StatesContact added r•••@phci.orgContact added (no phone or email listed)
  • ProHealth Oconomowoc Memorial Hospital · Oconomowoc, United StatesContact added •••7878Contact added (no phone or email listed)
  • UW Cancer Center at ProHealth Care · Waukesha, United StatesContact added C•••@phci.org · •••5539Contact added (no phone or email listed)
  • Yale University · New Haven, United StatesContact person changed (no phone or email listed)
  • Smilow Cancer Hospital Care Center-Trumbull · Trumbull, United StatesContact person changed (no phone or email listed)
  • Smilow Cancer Hospital Care Center - Waterford · Waterford, United StatesContact person changed (no phone or email listed)
  • Siteman Cancer Center at West County Hospital · Creve Coeur, United StatesContact added i•••@siteman.wustl.edu · •••3606Contact added (no phone or email listed)
across 2 updates, Oct 2, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    25 sites added. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Siteman Cancer Center at West County Hospital · Creve Coeur, United StatesSuspended→Recruiting
    • Swedish Medical Center-First Hill · Seattle, United StatesSuspended→Recruiting
    Show 25 added (25 United States)
    • Saint Joseph's Hospital and Medical Center · Phoenix, United States
    • Kaiser Permanente-Anaheim · Anaheim, United States
    • Kaiser Permanente-Bellflower · Bellflower, United States
    • Kaiser Permanente Los Angeles Medical Center · Los Angeles, United States
    • Kaiser Permanente-Ontario · Ontario, United States
    • Poudre Valley Hospital · Fort Collins, United States
    • Cancer Care and Hematology-Fort Collins · Fort Collins, United States
    • UCHealth Greeley Hospital · Greeley, United States
    • Medical Center of the Rockies · Loveland, United States
    • Tampa General Hospital · Tampa, United States
    • Rush MD Anderson Cancer Center · Chicago, United States
    • Carle at The Riverfront · Danville, United States
    • Carle Physician Group-Effingham · Effingham, United States
    • Carle Physician Group-Mattoon/Charleston · Mattoon, United States
    • Rush MD Anderson Cancer Center at Rush Oak Park · Oak Park, United States
    • Carle Cancer Center · Urbana, United States
    • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center · Lebanon, United States
    • Morristown Medical Center · Morristown, United States
    • Overlook Hospital · Summit, United States
    • Duke University Medical Center · Durham, United States
    • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center · Houston, United States
    • Ben Taub General Hospital · Houston, United States
    • VCU Massey Comprehensive Cancer Center · Richmond, United States
    • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · Madison, United States
    • University of Wisconsin Carbone Cancer Center - University Hospital · Madison, United States
    Site contacts Changed at 7 sites. See the sites
    Show 7 sites
    • Yale University · New Haven, United StatesContact person changed (no phone or email listed)
    • Smilow Cancer Hospital Care Center-Trumbull · Trumbull, United StatesContact person changed (no phone or email listed)
    • Smilow Cancer Hospital Care Center - Waterford · Waterford, United StatesContact person changed (no phone or email listed)
    • Siteman Cancer Center at West County Hospital · Creve Coeur, United StatesContact added i•••@siteman.wustl.edu · •••3606Contact added (no phone or email listed)
    • Providence Portland Medical Center · Portland, United StatesContact person changed (no phone or email listed)
    • Providence Saint Vincent Medical Center · Portland, United StatesContact person changed (no phone or email listed)
    • Swedish Medical Center-First Hill · Seattle, United StatesContact added P•••@swedish.org · •••2343Contact added (no phone or email listed)
    + 1 other change: verification date
  2. Oct 2, 2026
    31 sites added. 4 sites changed recruiting status (3 now recruiting, 1 now suspended)
    Show 4 sites
    • Swedish Medical Center-First Hill · Seattle, United StatesRecruiting→Suspended
    • ProHealth D N Greenwald Center · Mukwonago, United StatesSuspended→Recruiting
    • ProHealth Oconomowoc Memorial Hospital · Oconomowoc, United StatesSuspended→Recruiting
    • UW Cancer Center at ProHealth Care · Waukesha, United StatesSuspended→Recruiting
    Show 31 added (31 United States)
    • Kaiser Permanente Dublin · Dublin, United States
    • Kaiser Permanente-Fremont · Fremont, United States
    • Kaiser Permanente Fresno Orchard Plaza · Fresno, United States
    • Kaiser Permanente-Fresno · Fresno, United States
    • Kaiser Permanente- Modesto MOB II · Modesto, United States
    • Kaiser Permanente-Oakland · Oakland, United States
    • Kaiser Permanente-Roseville · Roseville, United States
    • Kaiser Permanente Downtown Commons · Sacramento, United States
    • Kaiser Permanente-South Sacramento · Sacramento, United States
    • Kaiser Permanente-San Francisco · San Francisco, United States
    • Kaiser Permanente-Santa Teresa-San Jose · San Jose, United States
    • Kaiser Permanente San Leandro · San Leandro, United States
    • Kaiser San Rafael-Gallinas · San Rafael, United States
    • Kaiser Permanente Medical Center - Santa Clara · Santa Clara, United States
    • Kaiser Permanente-Santa Rosa · Santa Rosa, United States
    • Kaiser Permanente-South San Francisco · South San Francisco, United States
    • Kaiser Permanente-Vallejo · Vallejo, United States
    • Kaiser Permanente-Walnut Creek · Walnut Creek, United States
    • John Muir Medical Center-Walnut Creek · Walnut Creek, United States
    • Augusta University Medical Center · Augusta, United States
    • Lawrence Memorial Hospital · Lawrence, United States
    • Massachusetts General Hospital Cancer Center · Boston, United States
    • Dana-Farber Cancer Institute · Boston, United States
    • Abbott-Northwestern Hospital · Minneapolis, United States
    • University of Mississippi Medical Center · Jackson, United States
    • Siteman Cancer Center at Saint Peters Hospital · City of Saint Peters, United States
    • Siteman Cancer Center at West County Hospital · Creve Coeur, United States
    • Washington University School of Medicine · St Louis, United States
    • Siteman Cancer Center-South County · St Louis, United States
    • Siteman Cancer Center at Christian Hospital · St Louis, United States
    • …and 1 more on the registry record
    Site contacts Changed at 8 sites. See the sites
    Show 8 sites
    • Providence Portland Medical Center · Portland, United StatesContact person changed (no phone or email listed)
    • Providence Saint Vincent Medical Center · Portland, United StatesContact person changed (no phone or email listed)
    • University of Vermont Medical Center · Burlington, United StatesContact person changed (no phone or email listed)
    • University of Vermont and State Agricultural College · Burlington, United StatesContact person changed (no phone or email listed)
    • Swedish Medical Center-First Hill · Seattle, United StatesContact removed P•••@swedish.org · •••2343Contact removed (no phone or email listed)
    • ProHealth D N Greenwald Center · Mukwonago, United StatesContact added r•••@phci.orgContact added (no phone or email listed)
    • ProHealth Oconomowoc Memorial Hospital · Oconomowoc, United StatesContact added •••7878Contact added (no phone or email listed)
    • UW Cancer Center at ProHealth Care · Waukesha, United StatesContact added C•••@phci.org · •••5539Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07215910
Responsible party
Sponsor
First posted
Oct 14, 2025
Start date
Jun 24, 2026
Primary completion
May 31, 2033 (estimated)
Completion
Jan 2040 (estimated)
Last update
Nov 3, 2026

Study contacts

Alexandra Alexandra LeVasseur
Contact
alevasseur@bsd.uchicago.edu
773-834-4518
Ugonma N Chukwueke, MD
study chair · Alliance for Clinical Trials in Oncology
Rifaquat M. Rahman, MD
study chair · Alliance for Clinical Trials in Oncology
Patrick Y Wen, MD
study chair · Alliance for Clinical Trials in Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorasidenib

Start the discussion